Aquagen International, Inc. Releases Results From Clinical Study

SALT LAKE CITY, April 20 /PRNewswire-FirstCall/ -- Aquagen International, Inc. , today released the results from a clinical study completed at the University of Cairo.

"This study was commissioned by the medical school at the University of Cairo in 2001 and the results were made available to us, but we just recently received authorization to release the study's terms, protocols and results to the public," said Joanne Clinger, Aquagen's CEO. "The study was titled, 'ORAL OXYGEN THERAPY in Combination with the Usual Lines of Treatment used in Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Pulmonary Fibrosis (IPF),' and the 50 human patients (28 suffered from COPD and 22 from IPF) were given the Aquagen(R) product and treated with standard therapy to determine if oxygen levels increased during treatment and helped the COPD and IPF treatments," said Clinger.

"The results were quite amazing, in that the study's administrators determined that there was significant improvement of the partial oxygen pressure in both the COPD and IPF patients," said Wayne Reichmann, President of Aquagen's wholly owned subsidiary, Aquagen Manufacturing. "In addition, there was significant reduction of blood-carbon dioxide levels in all patients and the study found that Aquagen(R) was helpful in the management of hypoxaemia in COPD and IPF patients and that the use of Aquagen(R) was synergistic when using standard COPD and IPF treatments," said Reichmann. "These studies have not been passed on by the FDA, but they are independent studies that show the efficacy of our Aquagen product for COPD and IPF treatments," said Clinger. "We will post a summary of this study on our website in the next few days and anyone interested can find review the summary on our website at http://www.aquagen.com/," said Reichmann.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements. "

Aquagen International, Inc.

CONTACT: Wayne Reichmann for Aquagen International, Inc.,+1-801-484-2777

Back to news